← Eichor
Study identifier: NCT06339658 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

Condition: Breast Cancer · Axillary Metastases  ·  Sponsor: Hospital Universitari de Bellvitge

PhaseN/A
Planned participants43
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Amparo Garcia-Tejedor  ·  0034-660223417  ·  agarciat@bellvitgehospital.cat

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital de BellvitgeL'Hospitalet de Llobregat, Barcelona, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06339658